Abstract
<strong>PICO question</strong><br /><p>Of cats that present with aortic thromboembolism, do patients that receive thrombolytic therapy in the acute phase have improved survival as compared to those who do not?</p><strong>Clinical bottom line</strong><br /><p>Based on the current available evidence, the use of thrombolytic therapy in the acute phase of aortic thromboembolism (ATE) does not appear to improve survival when compared to conventional supportive therapy. Frequently reported adverse side effects further questions its merits, and large scale controlled clinical trials would be required to further evaluate any benefit in the use of this therapy.</p><br /> <img src="https://www.veterinaryevidence.org/rcvskmod/icons/oa-icon.jpg" alt="Open Access" /> <img src="https://www.veterinaryevidence.org/rcvskmod/icons/pr-icon.jpg" alt="Peer Reviewed" />
Highlights
Treatment and number of cases: o Aspirin (75 mg EOD) - 21 o Furosemide (1–4 mg/kg) - 19 o Heparin (500–200 iu/kg [3,4] times daily) - 12 o Acepromazine (ACP) [0.05–0.2 mg/kg twice daily (BID)] - 10 o Nine cats received a combination of furosemide, heparin, aspirin and buprenorphine o Eight cats received cyproheptadine (2 mg BID) o Other treatments included oxygen therapy, diltiazem, non-steroidal anti-inflammatory drugs (NSAIDs) and angiotensin-converting-enzyme (ACE) inhibitors
Outcome studied: Evaluation of records of cats presenting to a first opinion veterinary hospital with clinical signs of distal aortic thromboembolism
Cats with clinical signs of arterial thromboembolism (ATE) presenting to two hospitals between 1992–1998 treated with streptokinase (SK) o Definition: dysfunction in one or two limbs and lack of arterial pulse in affected limb
Summary
ISSN: 2396-9776 Published: 06 Jun 2019 in: Vol 4, Issue 2 DOI: http://dx.doi.org/10.18849/ve.v4i2.212 Reviewed by: Theodora Tsouloufi (DVM, PhD, MRCVS) and Melanie Hezzell (MA(Cantab.), VetMB(Cantab.), PhD(RVC), CertVDI, CertVC, MRCVS, DACVIM) Next Review Date: 20 Jan 2020
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
